{
    "schema": 1,
    "fid": "retatrutide-tirzepatide",
    "type": "article",
    "object_id": 776,
    "title": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
    "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
    "url": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide",
    "facts_url": "https://www.preppinpeppers.com/facts/retatrutide-tirzepatide",
    "currency": null,
    "tldr": "Retatrutide plus Tirzepatide is a community- and vendor-named pairing, not a manufacturer combination. How the two reported receptor profiles overlap.",
    "facts": [
        {
            "id": "retatrutide-tirzepatide:title",
            "category": "identity",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "title",
            "value": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:published",
            "category": "identity",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "published",
            "value": "2026-08-18",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:author",
            "category": "identity",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "author",
            "value": "Preppin' Peppers Editorial Team",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:topics",
            "category": "identity",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "topics",
            "value": "research, stacks",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:summary",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "summary",
            "value": "Retatrutide plus Tirzepatide is a community- and vendor-named pairing, not a manufacturer combination. How the two reported receptor profiles overlap.",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:section-1",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "section",
            "value": "What it is",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:section-2",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "section",
            "value": "What it is",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:section-3",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "section",
            "value": "Why these are combined",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:section-4",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "section",
            "value": "What is not known",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:section-5",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "section",
            "value": "The components",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:section-6",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "section",
            "value": "Reconstitution and blending",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:section-7",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "section",
            "value": "Status in sport",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:section-8",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "section",
            "value": "Related reading",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:section-10",
            "category": "content",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "section",
            "value": "What the research community gets wrong about Retatrutide + Tirzepatide",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide"
        },
        {
            "id": "retatrutide-tirzepatide:source-www-nejm-org",
            "category": "source",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "cites",
            "value": "Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity : A Phase 2 Trial. N Engl J Med, 2023 - www.nejm.org",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.nejm.org/doi/full/10.1056/NEJMoa2301972"
        },
        {
            "id": "retatrutide-tirzepatide:source-pubchem-ncbi-nlm-nih-gov",
            "category": "source",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "cites",
            "value": "NCBI PubChem CID 156588324: Tirzepatide (C225H348N48O68) - pubchem.ncbi.nlm.nih.gov",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://pubchem.ncbi.nlm.nih.gov/compound/156588324"
        },
        {
            "id": "retatrutide-tirzepatide:source-www-ncbi-nlm-nih-gov",
            "category": "source",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "cites",
            "value": "Goldney et al., Curr Cardiovasc Risk Rep 2025: Triple Agonism Based Therapies for Obesity - www.ncbi.nlm.nih.gov",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304053/"
        },
        {
            "id": "retatrutide-tirzepatide:source-pmc-ncbi-nlm-nih-gov",
            "category": "source",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "cites",
            "value": "Katsi et al., Biomolecules 2025: Retatrutide-A Game Changer in Obesity Pharmacotherapy - pmc.ncbi.nlm.nih.gov",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/"
        },
        {
            "id": "retatrutide-tirzepatide:source-pmc-ncbi-nlm-nih-gov-2",
            "category": "source",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "cites",
            "value": "Nauck and D'Alessio, Cardiovasc Diabetol 2022: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction - pmc.ncbi.nlm.nih.gov",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9438179/"
        },
        {
            "id": "retatrutide-tirzepatide:source-pubmed-ncbi-nlm-nih-gov",
            "category": "source",
            "entity": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "attribute": "cites",
            "value": "Jastreboff et al., N Engl J Med 2022: Tirzepatide Once Weekly for the Treatment of Obesity - pubmed.ncbi.nlm.nih.gov",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide)",
            "evidence": "https://pubmed.ncbi.nlm.nih.gov/35658024/"
        }
    ],
    "buy": [],
    "faq": [
        {
            "q": "Has Retatrutide plus Tirzepatide been studied in a clinical trial?",
            "a": "No. Both compounds have published trial records individually, but no clinical study has evaluated them in combination. Any claim about what the pairing does is extrapolation."
        },
        {
            "q": "What is AMP-2P?",
            "a": "AMP-2P is a vendor product name applied to a two-peptide research blend in the incretin family. Sellers using it and comparable codes generally do not publish the composition, so the name identifies a catalogue item rather than a defined formulation. Treat the code as a search term, not a specification, and rely on an assay for identity."
        },
        {
            "q": "Do Retatrutide and Tirzepatide target different receptors?",
            "a": "They overlap. Retatrutide is a triple GLP-1/GIP/glucagon agonist and tirzepatide is a dual GIP/GLP-1 agonist, so both act on GLP-1 and GIP. The only receptor arm not shared is glucagon, which retatrutide already provides alone."
        },
        {
            "q": "Are these compounds banned under WADA rules for 2026?",
            "a": "GLP-1 compounds appear on the 2026 WADA Monitoring Program — tracked but not currently prohibited. WADA classification can change in future annual cycles, so verify against the current list."
        }
    ],
    "jsonld": [
        {
            "@context": "https://schema.org",
            "@type": "Article",
            "headline": "Retatrutide + Tirzepatide: What the Pairing Actually Is",
            "url": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide",
            "mainEntityOfPage": "https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide",
            "datePublished": "2026-08-18",
            "dateModified": "2026-10-16",
            "author": {
                "@type": "Person",
                "name": "Preppin' Peppers Editorial Team"
            },
            "publisher": {
                "@type": "Organization",
                "name": "PreppinPeppers"
            },
            "description": "Retatrutide plus Tirzepatide is a community- and vendor-named pairing, not a manufacturer combination. How the two reported receptor profiles overlap."
        },
        {
            "@context": "https://schema.org",
            "@type": "FAQPage",
            "url": "https://www.preppinpeppers.com/facts/retatrutide-tirzepatide",
            "mainEntity": [
                {
                    "@type": "Question",
                    "name": "Has Retatrutide plus Tirzepatide been studied in a clinical trial?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "No. Both compounds have published trial records individually, but no clinical study has evaluated them in combination. Any claim about what the pairing does is extrapolation."
                    }
                },
                {
                    "@type": "Question",
                    "name": "What is AMP-2P?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "AMP-2P is a vendor product name applied to a two-peptide research blend in the incretin family. Sellers using it and comparable codes generally do not publish the composition, so the name identifies a catalogue item rather than a defined formulation. Treat the code as a search term, not a specification, and rely on an assay for identity."
                    }
                },
                {
                    "@type": "Question",
                    "name": "Do Retatrutide and Tirzepatide target different receptors?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "They overlap. Retatrutide is a triple GLP-1/GIP/glucagon agonist and tirzepatide is a dual GIP/GLP-1 agonist, so both act on GLP-1 and GIP. The only receptor arm not shared is glucagon, which retatrutide already provides alone."
                    }
                },
                {
                    "@type": "Question",
                    "name": "Are these compounds banned under WADA rules for 2026?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "GLP-1 compounds appear on the 2026 WADA Monitoring Program — tracked but not currently prohibited. WADA classification can change in future annual cycles, so verify against the current list."
                    }
                }
            ]
        }
    ],
    "dates": {
        "published": "2026-08-18",
        "modified": "2026-10-16"
    }
}